Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands)¹, 9 October 2017

Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

Notification of Evermore Global Advisors, LLC, received on 6 October 2017

- On 6 October 2017, Fagron received a notification that the shareholding of Evermore Global Advisors,
 a person that notifies alone, has crossed the disclosure threshold of 3% on 18 May 2017 as the result
 of the acquisition of voting securities or voting rights.
- On the notification date, Evermore Global Advisors held a total of 2,203,472 voting rights.
- Based on the denominator of 71,843,904 (total number of voting rights), in total Evermore Global Advisors held on the notification date 3.07% of the total number of voting rights.
- Evermore Global Advisors is not a controlled undertaking.
- The notification of Evermore Global Advisors can be viewed on investors.fagron.com via this link.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For more information:

Constantijn van Rietschoten Chief Communications Officer Tel. +31 6 53 69 15 85 constantijn.van.rietschoten@fagron.com

Fagron profile

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 34 countries worldwide.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

